Weiping Lyu

433 total citations
26 papers, 311 citations indexed

About

Weiping Lyu is a scholar working on Molecular Biology, Pharmacology and Computational Theory and Mathematics. According to data from OpenAlex, Weiping Lyu has authored 26 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Pharmacology and 6 papers in Computational Theory and Mathematics. Recurrent topics in Weiping Lyu's work include Cholinesterase and Neurodegenerative Diseases (10 papers), Alzheimer's disease research and treatments (6 papers) and Computational Drug Discovery Methods (6 papers). Weiping Lyu is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (10 papers), Alzheimer's disease research and treatments (6 papers) and Computational Drug Discovery Methods (6 papers). Weiping Lyu collaborates with scholars based in China and Czechia. Weiping Lyu's co-authors include Haopeng Sun, Wenyuan Liu, Siyu He, Qinghong Liao, Feng Feng, Qihang Li, Song Song, Ying Chen, Baichen Xiong and Ning Jiao and has published in prestigious journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and Analytical and Bioanalytical Chemistry.

In The Last Decade

Weiping Lyu

25 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Weiping Lyu China 10 124 109 91 84 51 26 311
Wenrui Li China 9 128 1.0× 81 0.7× 79 0.9× 73 0.9× 91 1.8× 13 336
Qihang Li China 12 229 1.8× 157 1.4× 104 1.1× 159 1.9× 65 1.3× 29 448
Van-Hai Hoang South Korea 13 60 0.5× 229 2.1× 111 1.2× 78 0.9× 73 1.4× 29 424
Akash Marathakam India 10 126 1.0× 121 1.1× 97 1.1× 61 0.7× 57 1.1× 19 381
P. N. Shevtsov Russia 13 136 1.1× 115 1.1× 188 2.1× 94 1.1× 63 1.2× 32 365
Saba Shahzadi Pakistan 9 48 0.4× 94 0.9× 57 0.6× 56 0.7× 35 0.7× 32 294
Diones Bueno Brazil 10 53 0.4× 128 1.2× 52 0.6× 43 0.5× 23 0.5× 19 296
Gülru Kayık Türkiye 9 106 0.9× 148 1.4× 91 1.0× 70 0.8× 31 0.6× 14 312
Mohammed Samim India 14 70 0.6× 195 1.8× 233 2.6× 46 0.5× 29 0.6× 25 518
Hee-Jin Ha South Korea 13 60 0.5× 196 1.8× 114 1.3× 47 0.6× 132 2.6× 21 460

Countries citing papers authored by Weiping Lyu

Since Specialization
Citations

This map shows the geographic impact of Weiping Lyu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiping Lyu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiping Lyu more than expected).

Fields of papers citing papers by Weiping Lyu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiping Lyu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiping Lyu. The network helps show where Weiping Lyu may publish in the future.

Co-authorship network of co-authors of Weiping Lyu

This figure shows the co-authorship network connecting the top 25 collaborators of Weiping Lyu. A scholar is included among the top collaborators of Weiping Lyu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiping Lyu. Weiping Lyu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lyu, Weiping, et al.. (2026). Xanthine oxidase inhibitors for gout: Applications and novel drug development. European Journal of Medicinal Chemistry. 307. 118619–118619.
2.
Zhao, Yanping, Dehua Lu, Yanming Chen, et al.. (2025). Development of Potent SHP2 Allosteric Inhibitors: Design, Synthesis, and Evaluation with Antitumor Effects. Journal of Medicinal Chemistry. 68(5). 5238–5256. 1 indexed citations
3.
Lyu, Weiping, Jie Yu, Yanming Chen, et al.. (2024). Scaffold hopping-driven optimization for the identification of NLRP3 inhibitors as potential gout therapeutics. European Journal of Medicinal Chemistry. 279. 116881–116881. 1 indexed citations
4.
Lyu, Weiping, Shi Cheng, Kangchen Zhao, et al.. (2024). Novel mechanistic insights – A brand new Era for anti-HBV drugs. European Journal of Medicinal Chemistry. 279. 116854–116854. 6 indexed citations
5.
Li, Chao, Hongye Wang, Zixi Yan, et al.. (2024). C—F Bond Insertion into Indoles with CHBr2F: An Efficient Method to Synthesize Fluorinated Quinolines and Quinolones. Chinese Journal of Chemistry. 42(10). 1128–1132. 21 indexed citations
6.
Lyu, Weiping, Yanming Chen, Ruohan Yu, et al.. (2024). Design, synthesis, and pharmacological characterization of sulfonylurea-based NLRP3 inhibitors: Towards an effective therapeutic strategy for Alzheimer's disease. European Journal of Medicinal Chemistry. 280. 116993–116993. 1 indexed citations
7.
Liao, Qinghong, He Huang, Siyu He, et al.. (2024). Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases. European Journal of Medicinal Chemistry. 271. 116386–116386. 6 indexed citations
8.
Wang, Kaixuan, Qinghong Liao, Siyu He, et al.. (2024). A new strategy for the treatment of Parkinson’s disease: Discovery and bio-evaluation of the first central-targeting tyrosinase inhibitor. Bioorganic Chemistry. 150. 107612–107612. 6 indexed citations
9.
Lyu, Weiping, Bo Qiang, Yanming Chen, et al.. (2024). Deep-Learning-Driven Discovery of SN3–1, a Potent NLRP3 Inhibitor with Therapeutic Potential for Inflammatory Diseases. Journal of Medicinal Chemistry. 67(19). 17833–17854. 6 indexed citations
10.
Chen, Ying, Weiting Zhang, Qi Li, et al.. (2024). Discovery of 4-benzylpiperazinequinoline BChE inhibitor that suppresses neuroinflammation for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry. 272. 116463–116463. 9 indexed citations
11.
Wang, Kaixuan, et al.. (2023). Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects. European Journal of Medicinal Chemistry. 265. 116065–116065. 26 indexed citations
12.
Liu, Chang, Weiping Lyu, Jian Xu, et al.. (2023). Discovery of thiazole salt AChE inhibitors and development of thiamine disulfide prodrugs targeting the central nervous system. Bioorganic Chemistry. 139. 106702–106702. 6 indexed citations
13.
Zhang, Xiangyu, Xiaowei Chi, Weiping Lyu, et al.. (2023). Discovery of NLRP3 inhibitors using machine learning: Identification of a hit compound to treat NLRP3 activation-driven diseases. European Journal of Medicinal Chemistry. 260. 115784–115784. 5 indexed citations
14.
Du, Chenxi, Lei Wang, Hongyu Yang, et al.. (2022). N-Benzyl Benzamide Derivatives as Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer’s Disease. Journal of Medicinal Chemistry. 65(16). 11365–11387. 34 indexed citations
15.
Wang, Yuanyuan, Baichen Xiong, Hongzhi Lin, et al.. (2022). Design, synthesis and evaluation of fused hybrids with acetylcholinesterase inhibiting and Nrf2 activating functions for Alzheimer's disease. European Journal of Medicinal Chemistry. 244. 114806–114806. 21 indexed citations
16.
Li, Qi, Baichen Xiong, Yuanyuan Wang, et al.. (2022). A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement. European Journal of Medicinal Chemistry. 239. 114510–114510. 18 indexed citations
17.
18.
Wang, Huai‐Song, Yingming Wang, Weiping Lyu, et al.. (2021). Anti-cancer adjuvant drug screening via epithelial-mesenchymal transition-related aptamer probe. Analytical and Bioanalytical Chemistry. 413(28). 6951–6962. 3 indexed citations
19.
20.
Jiang, Xueyang, Yang Wang, Yingming Wang, et al.. (2020). Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer’s disease. Bioorganic & Medicinal Chemistry. 30. 115940–115940. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wenrui Li Breakdown of academic impact, for papers by Qihang Li Breakdown of academic impact, for papers by Van-Hai Hoang Breakdown of academic impact, for papers by Akash Marathakam Breakdown of academic impact, for papers by P. N. Shevtsov Breakdown of academic impact, for papers by Saba Shahzadi Breakdown of academic impact, for papers by Diones Bueno Breakdown of academic impact, for papers by Gülru Kayık Breakdown of academic impact, for papers by Mohammed Samim Breakdown of academic impact, for papers by Hee-Jin Ha
Rankless by CCL
2026